Navigation Links
Novel treatments show improvements in survival and response rates for leukemia and lymphoma
Date:12/6/2008

with diffuse large B-cell lymphoma (23 patients), those with follicular lymphoma (21 patients), and those with other B-cell non-Hodgkin lymphomas (24 patients), including chronic lymphocytic leukemia/small lymphocytic lymphoma (11 patients), mantle cell lymphoma (nine patients), MALT lymphoma (three patients), and lymphoplasmacytic non-Hodgkin lymphoma (one patient). Patients previously received an average of five therapies, and many had previously received an autologous stem cell transplant or radioimmunotherapy.

The study found that fostamatinib disodium produced complete or partial responses in 21 percent of patients with diffuse large B-cell lymphoma, 54 percent of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, 11 percent of mantle cell lymphoma patients, and 10 percent of those with follicular lymphoma. Stable disease was also seen in an additional 23 patients, including 12 with follicular lymphoma, four with diffuse large B-cell lymphoma, four with mantle cell lymphoma, two with chronic lymphocytic leukemia/small lymphocytic lymphoma, and one with MALT lymphoma. A proportion of these responses was prolonged, with some patients remaining on therapy for more than one year. Given the refractory nature of these patients' lymphoma, the toxicity profile was quite favorable.

There were four cases of febrile neutropenia with eight patients requiring a dose-modification due to neutropenia, hypertension, liver function test abnormalities, fever, and mucositis.

Dexamethasone in Induction Can Eliminate One-Third of All Relapses in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 3,655 Patients (Trial AIEOP-BFM ALL 2000) [Abstract #7]
Martin Schrappe, MD, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

The results of this study found that the use of dexamethasone in the induction phase of combination chemotherapy led to a one-
'/>"/>

Contact: Laura Stark
lstark@hematology.org
415-978-3505
American Society of Hematology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email: